| Drug General Information |
| Drug ID |
D0Y0FS
|
| Former ID |
DNC002424
|
| Drug Name |
6-Nitroindazole
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C7H5N3O2
|
| Canonical SMILES |
C1=CC2=C(C=C1[N+](=O)[O-])NN=C2
|
| InChI |
1S/C7H5N3O2/c11-10(12)6-2-1-5-4-8-9-7(5)3-6/h1-4H,(H,8,9)
|
| InChIKey |
ORZRMRUXSPNQQL-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| PubChem Substance ID |
92375, 106062, 592911, 609765, 826400, 826426, 3134057, 5803796, 7736862, 7885466, 8139969, 8167695, 10535013, 11113657, 14772469, 17153724, 24897520, 29291326, 46504479, 49748239, 49982567, 51075372, 56423145, 57331634, 71833219, 78766667, 81043639, 87573744, 88814035, 92321658, 92712040, 103239666, 104126535, 104359722, 104669793, 117378587, 117378936, 118023947, 118083083, 124800346, 125357305, 126582033, 126630278, 126656972, 126670750, 126738811, 127324233, 127324234, 127324235, 127324236
|
| Target and Pathway |
| Target(s) |
Nitric-oxide synthase, endothelial |
Target Info |
Inhibitor |
[1]
|
|---|
| Nitric oxide synthase, inducible |
Target Info |
Inhibitor |
[1]
|
|
BioCyc Pathway
|
Citrulline-nitric oxide cyclePWY-4983:Citrulline-nitric oxide cycle
|
|
KEGG Pathway
|
Arginine and proline metabolism
|
|
Metabolic pathways
|
|
Calcium signaling pathway
|
|
cGMP-PKG signaling pathway
|
|
HIF-1 signaling pathway
|
|
Sphingolipid signaling pathway
|
|
PI3K-Akt signaling pathway
|
|
VEGF signaling pathway
|
|
Platelet activation
|
|
Estrogen signaling pathway
|
|
Oxytocin signaling pathwayhsa00220:Arginine biosynthesis
|
|
Peroxisome
|
|
Salmonella infection
|
|
Pertussis
|
|
Leishmaniasis
|
|
Chagas disease (American trypanosomiasis)
|
|
Toxoplasmosis
|
|
Amoebiasis
|
|
Tuberculosis
|
|
Pathways in cancer
|
|
Small cell lung cancer
|
|
NetPath Pathway
|
Wnt Signaling PathwayNetPath_13:IL1 Signaling Pathway
|
|
IL2 Signaling Pathway
|
|
PANTHER Pathway
|
Angiogenesis
|
|
Endothelin signaling pathway
|
|
Interleukin signaling pathway
|
|
PI3 kinase pathway
|
|
VEGF signaling pathway
|
|
Pathway Interaction Database
|
Plasma membrane estrogen receptor signaling
|
|
Validated transcriptional targets of AP1 family members Fra1 and Fra2
|
|
Angiopoietin receptor Tie2-mediated signaling
|
|
Thromboxane A2 receptor signaling
|
|
SHP2 signaling
|
|
VEGFR1 specific signals
|
|
Signaling events mediated by VEGFR1 and VEGFR2
|
|
PAR1-mediated thrombin signaling eventsil12_2pathway:IL12-mediated signaling events
|
|
Alpha9 beta1 integrin signaling events
|
|
ATF-2 transcription factor network
|
|
IL23-mediated signaling events
|
|
Signaling mediated by p38-alpha and p38-beta
|
|
HIF-1-alpha transcription factor network
|
|
Reactome
|
ROS production in response to bacteria
|
|
Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
|
|
eNOS activation
|
|
Nitric oxide stimulates guanylate cyclase
|
|
VEGFR2 mediated vascular permeabilityR-HSA-1222556:ROS production in response to bacteria
|
|
WikiPathways
|
ACE Inhibitor Pathway
|
|
EGF/EGFR Signaling Pathway
|
|
Myometrial Relaxation and Contraction Pathways
|
|
JAK/STAT
|
|
Corticotropin-releasing hormone
|
|
AGE/RAGE pathway
|
|
Endothelin Pathways
|
|
Leptin signaling pathway
|
|
Effects of Nitric Oxide
|
|
Metabolism of nitric oxide
|
|
AngiogenesisWP619:Type II interferon signaling (IFNG)
|
|
Spinal Cord Injury
|
| References |
| REF 1 | How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. |
|---|
